NCT02185183已完成1 期
Phase 2 Clinical Trial for Oral Administration of Alequel for Patients With IBD
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 主要终点
- Number of Participants With Improved in Disease Activity
研究概览
简要总结
Oral administration of Alequel, a mixture of proteins derived from the patient's bowel will be tested in patients with inflammatory bowel disease.
详细描述
Oral administration of Alequel prepared from patients biopsies will be tested in patients with inflammatory bowel disease to determine its anti inflammatory effect.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Crohn's disease
排除标准
- •Immune suppression
研究组 & 干预措施
AlequelTM
Experimental
AlequelTM
干预措施: Alequel (Drug)
结局指标
主要结局
Number of Participants With Improved in Disease Activity
时间窗: 15 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study of Single and Multiple Doses of ALS-008176 in Healthy VolunteersRespiratory Syncytial Virus InfectionsNCT01906164Alios Biopharma Inc.101
已完成
2 期
A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and AdolescentsHIV-1HIV InfectionsNCT00355524Tibotec Pharmaceuticals, Ireland80
已完成
2 期
A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected ChildrenHuman Immunodeficiency Virus 1NCT00919854Tibotec Pharmaceuticals, Ireland27
已完成
1 期
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure DisordersSeizuresNCT02324673INSYS Therapeutics Inc61
已完成
2 期
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CChronic Hepatitis CNCT01790100Alios Biopharma Inc.20